Zimmer Biomet Holdings (ZBH) continues to demonstrate a promising future with its recent
upgrade by Evercore to Outperform and the reiteration of its 'Buy' rating by BTIG amid its
stable returns. Oak Family Advisors LLC, Absher Wealth Management LLC, Calamos Advisors LLC, and Boston Trust Walden Corp have significantly increased their positions in the company, highlighting investor confidence in ZBH's prospects. Moreover, the company's recent
acquisition of Monogram Technologies, coupled with FDA clearance for an enhanced version of ROSA® Knee Robotic Technology, bolsters its position in the market. Despite experiencing some turbulence, such as a
reduced growth forecast for 2025 and losses in Q3, experts are optimistic about the company's growth potential, underpinned by its innovative collaborations like the OneStep Mobility partnership, commitment to expanding its AI-Driven Orthopedic Robotics portfolio, and dedication to advancing musculoskeletal care. However, Zimmer Biomet's
valuation, investor’s reactions to its dividend move, mixed returns, and the pairing of a Q4 dividend with OneStep Mobility Analytics are aspects yet to be fully unravelled.
Zimmer Biomet Holdings ZBH News Analytics from Mon, 05 May 2025 07:00:00 GMT to Fri, 09 Jan 2026 20:03:55 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor 3
